Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma. Survival outcomes by insurance coverage in non-Hodgkin lymphoma (NHL): Experience from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results